Search Results

• Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

  Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)

• Unbalanced Atrioventricular Septal Defect Study

  Unbalanced Atrioventricular Septal Defect: A Congenital Heart Surgeons' Society Inception Cohort Study

• Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

  A Study Using Molecular Guided Therapy With Induction Chemotherapy Followed by a Randomized Controlled Trial of Standard Immunotherapy With or Without DFMO Followed by DFMO Maintenance for Subjects With Newly Diagnosed High-Risk Neuroblastoma

• NMTT- Neuroblastoma Maintenance Therapy Trial Using DFMO

  NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)

• CIBMTR Research Database

  Protocol For A Research Database For Hematopoietic Stem Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries

• VALIDATION OF THE SURGIMEASURE TOOL FOR REAL-TIME INTRAOPERATIVE DISTANCE MEASUREMENT USING DE-IDENTIFIED ROBOTIC AND LAPAROSCOPIC VIDEO DATA

  VALIDATION OF THE SURGIMEASURE TOOL FOR REAL-TIME INTRAOPERATIVE DISTANCE MEASUREMENT USING DE-IDENTIFIED ROBOTIC AND LAPAROSCOPIC VIDEO DATA

• DAY101 vs. Standard of Care Chemotherapy in Pediatric Patients With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

  LOGGIC/FIREFLY-2: A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients With Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy

• A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG)

  A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG)

• Phase 2 Study of Tovorafenib (DAY101) in Relapsed and Refractory Langerhans Cell Histiocytosis

  Phase 2 Study of Tovorafenib (DAY101) in Relapsed and Refractory Langerhans Cell Histiocytosis